Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: QSAM Biosciences Inc. QSAM

MissionIRNewsBreaks – QSAM Biosciences Inc. (OTCQB: QSAM) Releases Q2 2022 Financial Report, Corporate Update

QSAM Biosciences (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP, or CycloSam(R), for the treatment of bone cancer and related diseases, has reported on its financial results for Q2, the period ended June 30, 2022; the company also … Continue reading

Posted in QSAM Biosciences Inc. QSAM | Leave a comment

QSAM Biosciences Inc. (QSAM) Awarded Patent for Potential Breakthrough Bone Cancer Treatment

This is the third U.S. patent granted to QSAM, further strengthening its IP portfolio, which consists of 14 patents among three patent families.“CycloSam has potential to be a breakthrough therapy for both primary and secondary forms of bone cancer,” says … Continue reading

Posted in QSAM Biosciences Inc. QSAM | Leave a comment

MissionIRNewsBreaks – QSAM Biosciences Inc. (QSAM) Targeting Significant Unmet Medical Need with CycloSam(R)

QSAM Biosciences (OTCQB: QSAM) is a company developing a new class of drugs called radiopharmaceuticals that deliver radiation therapy directly and specifically to cancer cells. The company’s lead drug candidate, CycloSam(R), is a clinical-stage bone-seeking radiopharmaceutical designed to deliver targeted … Continue reading

Posted in QSAM Biosciences Inc. QSAM | Leave a comment

MissionIRNewsBreaks – Why QSAM Biosciences Inc. (QSAM) Is ‘One to Watch’

QSAM Biosciences (OTCQB: QSAM), a clinical-stage biotechnology company, is focused on bringing to market targeted therapeutic radiopharmaceuticals. “The company is committed to advancing the fight against cancer through the discovery, development and delivery of effective treatment options for adult and … Continue reading

Posted in QSAM Biosciences Inc. QSAM | Leave a comment

QSAM Biosciences Inc. (QSAM) Marks Milestone with Dosing of First Patient in CycloSam Clinical Trial

Treating patients with primary or secondary bone cancer remains goal, says company CEORadiopharmaceuticals is a new class of drugs that delivers radiation therapy directly to cancer cellsQSAM is working to develop CycloSam(R) as a breakthrough therapeutic for adult and pediatric bone … Continue reading

Posted in QSAM Biosciences Inc. QSAM | Leave a comment

QSAM Biosciences Inc. (QSAM) Is ‘One to Watch’

QSAM Biosciences Inc. is committed to advancing the fight against cancer through the discovery, development and delivery of effective treatment options for adult and pediatric patientsCycloSam(R), QSAM Biosciences’ initial technology, is a clinical-stage bone targeting radiopharmaceutical being evaluated for multiple … Continue reading

Posted in QSAM Biosciences Inc. QSAM | Leave a comment